This content requires Adobe Flash Player 8

Click Here to Download

Programs | Part 5: Drug Safety I: NSAIDs, Steroids, & DMARDs

View Broadcast

Release Date: Thursday, February 11, 2010
Expiration Date: Thursday, February 10, 2011
Cost: No Charge
   

Documents for Download
 
Program Materials
Part 5 Goal Tool
Program Evaluation
Sign In Sheet
CME/CE Request Form
Program Syllabus
Program Slides

 

This series is provided by   

To complete the on-line evaluation and credit request form and to print your certificate, choose the appropriate link:
 

The Outcome Tool Survey is now available for "Managing Rheumatoid Arthritis in the Primary Care Setting" participants 

Physician CME "Snack" Survey   CME Snacks are defined as continuing education activities certified/designated for less than 1.0 CME credit.

Early treatment of RA is critical to improve symptoms and reduce or stop erosive progression.  Traditional therapeutic classes of drugs include NSAIDs, steroids, and non-biologic DMARDs.  Patients, however, face the potential of adverse events related to the RA treatments.  For example, the Food and Drug Administration issued a warning that all NSAIDs, including COX-2 inhibitors, may cause an increased risk of serious blood clots, heart attacks and stroke.  Patients using glucocorticoids and DMARDs should also be carefully monitored for adverse events related to treatment. 

 
This program will review NSAIDs, steroids, and DMARD use; safety issues related to these treatments; and appropriate safety monitoring guidelines.
 
Target Audience
This program is intended for family practitioners, general internists, advanced nurse practitioners, physician assistants and other healthcare providers.
 
Program Objectives
  • Review the role of primary care in the management of rheumatoid arthritis (RA) and its comorbidities
  • Identify the clinical characteristics of RA and the concept of pattern recognition as it applies to chronic inflammatory arthritis
  • Identify histologic, anatomic, and physiologic considerations that contribute to the pathogenesis of RA
  • Describe treatment goals and/or outcome measures for managing RA
  • Devise strategies for implementing RA therapies to maximize their safety and efficacy
  • Apply evidence and best practices to manage the complexities of RA in the primary care setting
  • Describe the systemic complications of RA and integrate the treatment of comorbidities into patients' overall treatment plan
Faculty
John J. Cush, MD
Director of Clinical Rheumatology
Baylor Research Institute
Professor of Medicine and Rheumatology
Baylor University Medical Center
Clinical Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas
 
Dorothy D. Sherwood, MD, FACP
Private Practice
Internal Medicine & Geriatrics
HealthCore Physicians Group
Chief
Department of Geriatrics
Texas Health Presbyterian Hospital Dallas
Dallas, Texas
 
Release and Termination Dates
Release: Thursday, February 11, 2010
12:00 PM - 12:30 PM ET
Termination:  Thursday, February 10, 2011
 
Accreditation
Physician
The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
The University of Texas Southwestern Medical Center designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit. Physicians should only claim credit commensurate with the extent of their participation in the activity. 
 
Nursing
The Camenae Group, Inc, is an approved provider of continuing nursing education by the Texas Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.  This activity meets Type I criteria for mandatory continuing education requirements toward relicensure as established by the Board of Nursing.
 
The Camenae Group, Inc. provides up to 4.5 contact hours for successful completion of this educational activity (0.5 contact hours for each Part).
 
This activity is supported by educational donations provided by Amgen and Pfizer Inc.